1-5 of 5
Nairouz Elgeioushi
Close
Save search
Follow your search
Access your saved searches in your account
Would you like to receive an alert when new items match your search?
Close Modal
Sort by
Journal Articles

Safety and Tolerability of AZD0466 As Monotherapy for Patients with Advanced Hematologic Malignancies. Results from a Phase I/II Trial

Shukaib Arslan, Giovanni Marconi, Giovanni Martinelli, Shaun Fleming, Antonio Curti, Shira N. Dinner, James S Blachly, Matteo Giovanni Della Porta, Ashish Bajel, Tim Sauer, Martina Crysandt, Arnaud Pigneux, Lars Fransecky, Claudia D Baldus, Marina Y. Konopleva, Yotvat Marmor, Shringi Sharma, Nairouz Elgeioushi, Patricia Cheung, Emily Rowe, Ekaterina Jahn, Ting Yu, Jamal Saeh, Raoul Tibes, Fathima Zumla Cader, Nitin Jain
Journal: Blood
Blood (2023) 142 (Supplement 1): 5907.
https://doi.org/10.1182/blood-2023-179168
Published: 2023
Journal Articles

Safety and Tolerability of AZD0466 As Monotherapy for Patients with Advanced Hematological Malignancies. Preliminary Results from an Ongoing Phase I/II Trial

Shukaib Arslan, Shaun Fleming, Nitin Jain, Giovanni Martinelli, Anthony S. Stein, James S. Blachly, Ashish Bajel, Antonio Curti, Giovanni Marconi, Giulia Fabbri, Yotvat Marmor, Shringi Sharma, Nairouz Elgeioushi, Natalia Couto-Francisco, Jamal Saeh, Raoul Tibes, Fathima Zumla Cader, Marina Konopleva
Journal: Blood
Blood (2022) 140 (Supplement 1): 9091–9093.
https://doi.org/10.1182/blood-2022-166192
Published: 2022
Journal Articles

NIMBLE: A Phase I/II Study of AZD0466 Monotherapy or in Combination in Patients with Advanced Hematological Malignancies

Marina Konopleva, Nitin Jain, Courtney L Andersen, Natalia Couto Francisco, Nairouz Elgeioushi, Rosalind Hobson, Martin Scott, John Stone, Shringi Sharma, Pablo Morentin Gutierrez, Raoul Tibes, Barry Davies, Thomas Winkler, Giulia Fabbri, Fathima Zumla Cader, Nicole McNeer
Journal: Blood
Blood (2021) 138 (Supplement 1): 2353.
https://doi.org/10.1182/blood-2021-147482
Published: 2021
Journal Articles

Results of a Phase 2 Study of MEDI-551 and Bendamustine Vs Rituximab and Bendamustine in Relapsed or Refractory Chronic Lymphocytic Leukemia

Douglas Gladstone, MD, Marc Andre, MD PhD, Jan Zaucha, MD PhD, Sarit Assouline, MD MSc, Naresh Bellam, MD MPH, Nicole Cascavilla, MD, Eric Jourdan, MD PhD, Amit Panwalkar, MD, Caterina Patti, MD, Clemens Schulte, MD, Francesco Zaja, MD, Trishna Goswami, MD, Nairouz Elgeioushi, MPH, Katie Streicher, PhD, Haifeng Bao, PhD, David Spaner, MD FRCPC, PhD
Journal: Blood
Blood (2014) 124 (21): 4472.
https://doi.org/10.1182/blood.V124.21.4472.4472
Published: 2014
Journal Articles

Safety Profile and Clinical Response To MEDI-551, a Humanized Monoclonal Anti-CD19, In a Phase 1/2 Study In Adults With Relapsed Or Refractory Advanced B-Cell Malignancies

Andres Forero-Torres, MD, Mehdi Hamadani, MD, Michelle A. Fanale, MD, Celeste M. Bello, MD, Thomas J. Kipps, MD, PhD, Fritz Offner, MD, Gregor Verhoef, Massimo Federico, MD, Stephanie A. Gregory, MD, Anne Sonet, MD, Sarit Assouline, MD, Jaime Pérez de Oteyza, Jose Francisco Tomas, MD, Antonio Cuneo, MD, Nairouz Elgeioushi, MPH, Trishna Goswami, MD, Ramy Ibrahim, MD, Ronald Herbst, PhD, Bruce D. Cheson, M.D.
Journal: Blood
Blood (2013) 122 (21): 1810.
https://doi.org/10.1182/blood.V122.21.1810.1810
Published: 2013